Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Astellas Files Kiklin to Treat Non-Dialysis CKD Patients
March 18, 2015
- MSD Revving Up Detailing on Rotavirus, Hepatitis B Vaccines, Eyes Public Immunization Program
March 18, 2015
- Alirocumab Meets Primary Efficacy Endpoint in PIII Study: Sanofi
March 17, 2015
- Minophagen Seeks Approval for CTCL Treatment
March 17, 2015
- Selexipag Lowers Risk of Morbidity, Mortality Events by 40% in PIII Study
March 17, 2015
- AnGes MG Initiates PIII Study of Nucleotide NF-κB Decoy Oligo for Atopic Dermatitis
March 17, 2015
- ViiV Receives Approval for HIV Infection Treatment Triumeq
March 17, 2015
- Takecab Surged to Top Spot in January Anterio Ranking
March 16, 2015
- Meiji Seika Halts Development of Antiallergic Treatment, Terminating Pact with Amalyte
March 16, 2015
- Eisai Revises Deal with Epizyme on Cancer Therapies
March 13, 2015
- Santen Earns Approval for Preservative-Free Glaucoma Eye Drops
March 13, 2015
- Sanwa Kagaku Names Hata as Successor to Late President Yamamoto
March 13, 2015
- AZ Appoints BMKK’s Taniguchi as Head of R&D
March 13, 2015
- AZ Receives Approval for Bydureon Pen Formulation
March 13, 2015
- Takecab vs PPIs (3): Which Will Come Out on Top? Everything Now in the Hands of Frontline Prescribers
March 13, 2015
- Takeda Transfers HPV Vaccine License to Kaketsuken
March 12, 2015
- Takecab vs PPIs (2): Takecab to Initially Gain Share for H. pylori Eradication?
March 12, 2015
- AZ to Tap Rich Pipelines to Grow as Oncology Powerhouse
March 11, 2015
- Over Half of RA Patients Remained in Remission 1 Year After Stopping Enbrel: Prof. Yamanaka
March 11, 2015
- Alogliptin Demonstrates No Increased Risk of Heart Failure: Takeda
March 11, 2015
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…